Arixtra Injection, Solution
Product Images NDC 67457-594

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Arixtra (NDC 67457-594). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mylan Institutional Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 And 2 (Image 01)

Instructional illustrations showing correct use of a prefilled syringe for Arixtra (fondaparinux sodium) injection. Figure 1 demonstrates removing the cap from the syringe needle, and Figure 2 shows administration of the subcutaneous injection into the abdominal area.*

FDA Label Image

Figure 3 And 4 (Image 02)

Two black and white instructional images showing subcutaneous injection technique. The first image (Figure 3) depicts a person preparing to inject a syringe into an area of the abdomen. The second image (Figure 4) shows the syringe inserted into the skin, with an arrow indicating the injection process. These illustrations likely demonstrate how to administer a subcutaneous injection.*

FDA Label Image

Fondaparinux Sodium Structural Formula (Image 03)

Chemical structure of fondaparinux sodium, the active ingredient in Arixtra injection solution. The diagram shows the molecular arrangement with sodium (Na) ions and functional groups characteristic of fondaparinux.*

FDA Label Image

Arixtra-syringe-1 (Image 04)

An instructional diagram of a syringe assembly for subcutaneous injection. The image shows numbered components including a needle cap, plunger, syringe barrel, and vial connector, illustrating parts involved in preparing and administering an injection.*

FDA Label Image

Arixtra-syringe-2 (Image 05)

An illustration of a syringe labeled with annotations. It shows the syringe plunger (2), barrel (3), and needle (4), representing a device used for administering injection solutions.*

FDA Label Image

Arixtra-syringe-3 (Image 06)

An instructional illustration showing a syringe labeled with numbers 2, 3, and 4, likely demonstrating steps or parts related to the preparation or administration of an injection. The syringe appears to have a cap or needle cover on the right side.*

FDA Label Image

Arixtra-figure-a (Image 07)

An instructional illustration showing a person preparing to administer a subcutaneous injection. The individual is seated on a cushioned surface with one leg bent and the other extended, holding the injection device near the abdomen area, demonstrating proper technique for subcutaneous injection.*

FDA Label Image

Arixtra-figure-b (Image 08)

A black and white illustration showing a hand holding a capped syringe and another hand removing the cap with a twisting motion, indicated by arrows. This instructional diagram likely demonstrates how to prepare the syringe for injection.*

FDA Label Image

Arixtra-figure-c (Image 09)

Black and white instructional illustration showing a person pressing their side abdomen with both hands. Two arrows point to the area being pressed, possibly indicating an injection site or a location relevant to the medication Arixtra (fondaparinux sodium) subcutaneous injection.*

FDA Label Image

Arixtra-figure-d (Image 10)

An instructional illustration showing a person administering a subcutaneous injection into the abdominal area using a syringe. The individual pinches the skin to prepare for the injection, consistent with common subcutaneous injection techniques.*

FDA Label Image

Arixtra-figure-e (Image 11)

An instructional black and white illustration showing a hand holding a syringe with a label marked 'Arixtra 7.5 mg' (fondaparinux sodium injection, solution) and an arrow pointing to the label area, demonstrating preparation or identification of the product for subcutaneous administration.*

FDA Label Image

Arixtra-figure-f (Image 12)

An instructional illustration displaying a hand holding a syringe for subcutaneous injection. An arrow indicates the direction or action in the injection procedure, emphasizing how to properly administer the injection.*

FDA Label Image

Arixtra Injection 2.5 mg/0.5 mL Carton Label (Image 13)

Packaging label for Arixtra (fondaparinux sodium injection, USP) 2.5 mg/0.5 mL, a subcutaneous injection by Mylan Institutional LLC. The label states it contains 10 single-dose, prefilled syringes with an automatic needle protection system and includes instructions for pharmacists to dispense the patient information leaflet.*

FDA Label Image

Arixtra Injection 5 mg/0.4 mL Carton Label (Image 14)

Packaging label for Arixtra 5 mg/0.4 mL injection, solution containing fondaparinux sodium for subcutaneous use. The label indicates it is a prescription drug by Mylan Institutional LLC. The box contains 10 single-dose, prefilled syringes equipped with an automatic needle protection system. The label includes directions for pharmacists to dispense a patient information leaflet with each package.*

FDA Label Image

Arixtra Injection 7.5 mg/0.6 mL Carton Label (Image 15)

Arixtra 7.5 mg/0.6 mL (fondaparinux sodium injection, USP) carton for subcutaneous injection. The label indicates it contains 10 single-dose prefilled syringes with an automatic needle protection system. Labeler is Mylan Institutional LLC. The packaging includes dosing information and storage instructions, highlighting Rx only status.*

FDA Label Image

Arixtra Injection 10 mg/0.8 mL Carton Label (Image 16)

Arixtra 10 mg/0.8 mL injection solution label for subcutaneous use. The packaging states the generic name fondaparinux sodium injection, USP, and indicates it contains 10 single-dose prefilled syringes with an automatic needle protection system. The label is from Mylan Institutional LLC and includes instructions for pharmacists to dispense an accompanying patient information leaflet.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.